Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies

Gene Therapy volume 16, pages 1245–1259 (2009)Cite this article

Abstract

Human complement receptors 1 and 2 are well described as important regulators of innate and adaptive immune responses, having pivotal roles in regulating complement activation (CR1) and B-cell maturation/survival. In contrast, the role of the murine homologs of CR1 and CR2 (mCR1/2) have been primarily defined as modulating activation of the adaptive immune system, with very little evidence available about the role of mCR1/2 in regulating the innate immune responses to pathogens. In this paper, we confirm that mCR1/2 plays an important role in regulating both the innate and adaptive immune responses noted after Adenovirus (Ad)-mediated gene transfer. Our results uncovered a novel role of mCR1/2 in downregulating several complement-dependent innate immune responses. We also unveiled the mechanism underlying the complement-dependent induction of neutralizing antibodies to Ad capsids as a CR1/2-dependent phenomenon that correlates with B-cell activation. These results confirm that Ad interactions with the complement system are pivotal in understanding how to maximize the safety or potency of Ad-mediated gene transfer for both gene therapy and vaccine applications.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Appledorn DM, McBride A, Seregin S, Scott JM, Schuldt N, Kiang A et al. Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Therapy 2008; 15: 1606–1617.

    Article  CAS  PubMed  Google Scholar 

  2. Zhu J, Huang X, Yang Y . Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus. J Immunol 2007; 178: 3505–3510.

    Article  CAS  PubMed  Google Scholar 

  3. Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009; 113: 1909–1918.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, Ross PJ et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452: 103–107.

    Article  CAS  PubMed  Google Scholar 

  5. Xu Z, Tian J, Smith JS, Byrnes AP . Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 2008; 82: 11705–11713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gasque P . Complement: a unique innate immune sensor for danger signals. Mol Immunol 2004; 41: 1089–1098.

    Article  CAS  PubMed  Google Scholar 

  7. Kawano M . Complement regulatory proteins and autoimmunity. Arch Immunol Ther Exp 2000; 48: 367–372.

    CAS  Google Scholar 

  8. Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM . Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett 2005; 97: 171–179.

    Article  CAS  PubMed  Google Scholar 

  9. Kemper C, Atkinson JP . T-cell regulation: with complements from innate immunity. Nat Rev 2007; 7: 9–18.

    Article  CAS  Google Scholar 

  10. Prechl J, Erdei A . Immunomodulatory functions of murine CR1/2. Immunopharmacology 2000; 49: 117–124.

    Article  CAS  PubMed  Google Scholar 

  11. Tedder TF, Inaoki M, Sato S . The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997; 6: 107–118.

    Article  CAS  PubMed  Google Scholar 

  12. Tedder TF, Haas KM, Poe JC . CD19-CD21 complex regulates an intrinsic Src family kinase amplification loop that links innate immunity with B-lymphocyte intracellular calcium responses. Biochem Soc Trans 2002; 30: 807–811.

    Article  CAS  PubMed  Google Scholar 

  13. Carroll MC . The complement system in B cell regulation. Mol Immunol 2004; 41: 141–146.

    Article  CAS  PubMed  Google Scholar 

  14. Boackle SA, Holers VM, Karp DR . CD21 augments antigen presentation in immune individuals. Eur J Immunol 1997; 27: 122–129.

    Article  CAS  PubMed  Google Scholar 

  15. Holers VM, Kulik L . Complement receptor 2, natural antibodies and innate immunity: inter-relationships in B cell selection and activation. Mol Immunol 2007; 44: 64–72.

    Article  CAS  PubMed  Google Scholar 

  16. Fairweather D, Frisancho-Kiss S, Njoku DB, Nyland JF, Kaya Z, Yusung SA et al. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J Immunol 2006; 176: 3516–3524.

    Article  CAS  PubMed  Google Scholar 

  17. Haas KM, Hasegawa M, Steeber DA, Poe JC, Zabel MD, Bock CB et al. Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity 2002; 17: 713–723.

    Article  CAS  PubMed  Google Scholar 

  18. Appledorn DM, Kiang A, McBride A, Jiang H, Seregin S, Scott JM et al. Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent. Gene Therapy 2008; 15: 885–901.

    Article  CAS  PubMed  Google Scholar 

  19. Hartman ZC, Appledorn DM, Amalfitano A . Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008; 132: 1–14.

    Article  CAS  PubMed  Google Scholar 

  20. Hartman ZC, Kiang A, Everett RS, Serra D, Yang XY, Clay TM et al. Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol 2007; 81: 1796–1812.

    Article  CAS  PubMed  Google Scholar 

  21. Kiang A, Hartman ZC, Everett RS, Serra D, Jiang H, Frank MM et al. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther 2006; 14: 588–598.

    Article  CAS  PubMed  Google Scholar 

  22. Li Y, Muruve DA, Collins RG, Lee SS, Kubes P . The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol 2002; 32: 3443–3452.

    Article  CAS  PubMed  Google Scholar 

  23. Liu Q, Zaiss AK, Colarusso P, Patel K, Haljan G, Wickham TJ et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 2003; 14: 627–643.

    Article  CAS  PubMed  Google Scholar 

  24. Schiedner G, Hertel S, Kochanek S . Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 2000; 11: 2105–2116.

    Article  CAS  PubMed  Google Scholar 

  25. Miwa K, Igawa A, Inoue H . Soluble E-selectin, ICAM-1 and VCAM-1 levels in systemic and coronary circulation in patients with variant angina. Cardiovasc Res 1997; 36: 37–44.

    Article  CAS  PubMed  Google Scholar 

  26. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148–158.

    Article  CAS  PubMed  Google Scholar 

  27. Manickan E, Smith JS, Tian J, Eggerman TL, Lozier JN, Muller J et al. Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther 2006; 13: 108–117.

    Article  CAS  PubMed  Google Scholar 

  28. Cotter MJ, Zaiss AK, Muruve DA . Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol 2005; 79: 14622–14631.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hu H, Serra D, Amalfitano A . Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum Gene Ther 1999; 10: 355–364.

    Article  CAS  PubMed  Google Scholar 

  30. Everett RS, Hodges BL, Ding EY, Xu F, Serra D, Amalfitano A . Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum Gene Ther 2003; 14: 1715–1726.

    Article  CAS  PubMed  Google Scholar 

  31. Hartman ZC, Black EP, Amalfitano A . Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology 2007; 358: 357–372.

    Article  CAS  PubMed  Google Scholar 

  32. Zinn KR, Szalai AJ, Stargel A, Krasnykh V, Chaudhuri TR . Bioluminescence imaging reveals a significant role for complement in liver transduction following intravenous delivery of adenovirus. Gene Therapy 2004; 11: 1482–1486.

    Article  CAS  PubMed  Google Scholar 

  33. Hawlisch H, Kohl J . Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol Immunol 2006; 43: 13–21.

    Article  CAS  PubMed  Google Scholar 

  34. Carroll M . Role of complement receptors CD21/CD35 in B lymphocyte activation and survival. Curr Top Microbiol Immunol 1999; 246: 63–68; discussion 69.

    CAS  PubMed  Google Scholar 

  35. Sato S, Miller AS, Howard MC, Tedder TF . Regulation of B lymphocyte development and activation by the CD19/CD21/CD81/Leu 13 complex requires the cytoplasmic domain of CD19. J Immunol 1997; 159: 3278–3287.

    CAS  PubMed  Google Scholar 

  36. Miwa T, Song WC . Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol 2001; 1: 445–459.

    Article  CAS  PubMed  Google Scholar 

  37. Miwa T, Zhou L, Tudoran R, Lambris JD, Madaio MP, Nangaku M et al. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity. Mol Immunol 2007; 44: 139–146.

    Article  CAS  PubMed  Google Scholar 

  38. Turnberg D, Botto M . The regulation of the complement system: insights from genetically-engineered mice. Mol Immunol 2003; 40: 145–153.

    Article  CAS  PubMed  Google Scholar 

  39. Moser B, Willimann K . Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis 2004; 63 (Suppl 2): ii84–ii89.

    CAS  PubMed Central  PubMed  Google Scholar 

  40. Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM et al. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol 2008; 82: 2727–2740.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Tian J, Xu Z, Smith JS, Hofherr SE, Barry MA, Byrnes AP . Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J Virol 2009; 83: 5648–5658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Croyle MA, Chirmule N, Zhang Y, Wilson JM . “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001; 75: 4792–4801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Ricklin D, Lambris JD . Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 2008; 632: 273–292.

    CAS  PubMed Central  PubMed  Google Scholar 

  44. Green TD, Newton BR, Rota PA, Xu Y, Robinson HL, Ross TM . C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 2001; 20: 242–248.

    Article  CAS  PubMed  Google Scholar 

  45. Ross TM, Xu Y, Bright RA, Robinson HL . C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 2000; 1: 127–131.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 2008; 14: 819–821.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ogun SA, Dumon-Seignovert L, Marchand JB, Holder AA, Hill F . The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria. Infect Immun 2008; 76: 3817–3823.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ricklin D, Lambris JD . Complement-targeted therapeutics. Nat Biotechnol 2007; 25: 1265–1275.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hodges BL, Evans HK, Everett RS, Ding EY, Serra D, Amalfitano A . Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications. J Virol 2001; 75: 5913–5920.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Ng P, Graham FL . Construction of first-generation adenoviral vectors. Methods Mol Med 2002; 69: 389–414.

    CAS  PubMed  Google Scholar 

  51. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS . Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926–933.

    CAS  PubMed Central  PubMed  Google Scholar 

  52. Gommerman JL, Oh DY, Zhou X, Tedder TF, Maurer M, Galli SJ et al. A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol 2000; 165: 6915–6921.

    Article  CAS  PubMed  Google Scholar 

  53. Hensley SE, Cun AS, Giles-Davis W, Li Y, Xiang Z, Lasaro MO et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther 2007; 15: 393–403.

    Article  CAS  PubMed  Google Scholar 

  54. Hofstetter JR, Zhang A, Mayeda AR, Guscar T, Nurnberger Jr JI, Lahiri DK . Genomic DNA from mice: a comparison of recovery methods and tissue sources. Biochem Mol Med 1997; 62: 197–202.

    Article  CAS  PubMed  Google Scholar 

  55. Loniewski KJ, Patial S, Parameswaran N . Sensitivity of TLR4- and -7-induced NF kappa B1 p105-TPL2-ERK pathway to TNF-receptor-associated-factor-6 revealed by RNAi in mouse macrophages. Mol Immunol 2007; 44: 3715–3723.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Michigan State University Laboratory Animal support facility for their assistance in the humane care and maintenance of the animals utilized in this work and Michigan State University Investigative Histopathology Laboratory for performing H&E stains of liver tissues. SSS was supported by American Heart Association Midwest Affiliate Fellowship 0815660G. AA was supported by the National Institutes of Health grants RO1DK-069884, P01 CA078673, the MSU Foundation as well the Osteopathic Heritage Foundation.

Author information

Authors and Affiliations

  1. Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA

    S S Seregin, Y A Aldhamen, D M Appledorn, N J Schuldt, A J McBride, M Bujold, S S Godbehere & A Amalfitano

  2. Department of Pediatrics, Michigan State University, East Lansing, MI, USA

    A Amalfitano

  3. Department of Pediatrics, Duke University Medical Center, Durham, NC, USA

    A Amalfitano

Authors
  1. S S Seregin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y A Aldhamen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D M Appledorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N J Schuldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A J McBride
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Bujold
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S S Godbehere
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Amalfitano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Amalfitano.

Additional information

Supplementary Information accompanies the paper on Gene Therapy website (http://www.nature.com/gt)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seregin, S., Aldhamen, Y., Appledorn, D. et al. CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies. Gene Ther 16, 1245–1259 (2009). https://doi.org/10.1038/gt.2009.77

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2009.77

Keywords

This article is cited by

Search

Advanced search

Quick links